Tianchang Group Reports Sharp Decline in E-cigarette Business Revenue in First Half of 2025, Revenue Drops by Over 50% from Previous Year

Sep.01.2025
Tianchang Group Reports Sharp Decline in E-cigarette Business Revenue in First Half of 2025, Revenue Drops by Over 50% from Previous Year
Tianchang Group has announced its interim results for 2025. During the reporting period, the e-cigarette business revenue was approximately 22.389 million Hong Kong dollars, a decrease of 52.5% compared to the same period in 2024 when it was 47.142 million Hong Kong dollars; the gross profit of the e-cigarette business was approximately 2.556 million Hong Kong dollars, lower than the 5.737 million Hong Kong dollars in the same period of the previous year.

Key Points:

 

·E-cigarette business revenue: In the first half of 2025, e-cigarette business revenue was approximately 22.389 million Hong Kong dollars, accounting for 8.8% of the total group revenue, a decrease of 52.5% from 47.142 million Hong Kong dollars in the same period in 2024. 

·Profitability: The gross profit of the e-cigarette business was approximately 2.556 million Hong Kong dollars, lower than the 5.737 million Hong Kong dollars in the same period of the previous year; the gross profit margin slightly decreased from 12.1% to 11.6%, mainly due to a decrease in sales volume leading to an increase in fixed costs per unit. 

·Business model: Manufacturing disposable e-cigarettes, refillable e-cigarettes, battery rods, atomizers, and heating tobacco devices as an OEM, selling them to overseas and mainland Chinese markets. 

·Compliance qualifications: Obtained the Tobacco Monopoly Administration of China's tobacco monopoly production enterprise license, valid until 2026. 

·Research and development investment: Research and development expenses for the period were approximately 7.4 million Hong Kong dollars, mainly used for the upgrade of core technology in e-cigarettes.

 


 

2Firsts, September 1, 2025 - Tianchang Group Holdings Limited (stock code: 2182) recently announced its interim performance for the six months ending on June 30, 2025.

 

The e-cigarette business data for the reporting period is as follows:

 

E-cigarette product revenue: approximately 22.389 million Hong Kong dollars, accounting for 8.8% of the total group revenue. This represents a decrease of about 52.5% from the same period in 2024, with a reduction of over half.

 

Profit from the e-cigarette business amounted to approximately HK$2.556 million, which is lower than the HK$5.737 million recorded in the same period last year.

 

Gross margin decreased slightly from 12.1% to 11.6%. The main reason for the decrease was a reduction in sales volume, which led to an increase in the allocation of fixed costs per unit product.

 

Business characteristics and strategies.

 

·Business model: The company acts as an original equipment manufacturer (OEM) producing disposable e-cigarettes, refillable e-cigarettes, battery rods, atomizers, and heating tobacco devices for sale in both overseas and domestic Chinese markets. 

·Compliance qualifications: The group has obtained a tobacco monopoly production license issued by the Chinese State Tobacco Monopoly Administration, valid until 2026. 

·Research and development investment: R&D spending during the period was approximately 7.4 million Hong Kong dollars, primarily used for upgrading the core technology of e-cigarettes.

 

According to reports, Tianchang Group is an integrated injection molding solution provider, focusing on mold design and production services as well as injection component design and manufacturing services. In recent years, the business has expanded to manufacturing e-cigarette products through OEM. Tianchang Group has previously provided OEM services for the e-cigarette brand "blu" under Imperial Tobacco.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio
Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio
Philip Morris Limited has announced the launch of Delia, the latest addition to its portfolio of heated tobacco and zero-tobacco sticks exclusively compatible with the IQOS Iluma range.
Apr.03 by 2FIRSTS.ai
LOST MARY Launches VIZ With Transparent Wraparound Pod and LED Display
LOST MARY Launches VIZ With Transparent Wraparound Pod and LED Display
LOST MARY announced VIZ on May 6, 2026, describing it as the brand’s first product with a transparent 360-degree wraparound pod.
May.07 by 2FIRSTS.ai
UK Opens Applications for Vaping Products Duty and Duty Stamps Scheme From April 1
UK Opens Applications for Vaping Products Duty and Duty Stamps Scheme From April 1
HM Revenue and Customs announced that from April 1, 2026, UK vaping product manufacturers, importers and warehousekeepers can apply for approval under Vaping Products Duty (VPD) and the Vaping Duty Stamps Scheme (VDS). Under new GOV.UK guidance, Vaping Products Duty will take effect on October 1, 2026 and will apply to all vaping liquids, whether they contain nicotine or not.
Apr.02 by 2FIRSTS.ai
Exhibition Insights | Geek Bar Booth Shows Two Fasoul Heat-Not-Burn Devices in Prague
Exhibition Insights | Geek Bar Booth Shows Two Fasoul Heat-Not-Burn Devices in Prague
At EVO NXT 2026 in Prague, the Geek Bar booth displayed two Fasoul heat-not-burn devices, Q1 Pro and C2. One stressed compact size, screen-led control and dual modes, while the other highlighted faster heating, a larger battery and added functions. Both were presented as compatible with IQOS TEREA and SENTIA sticks. Materials on a website displaying Fasoul-related information also show recent market activity in Japan and Italy.
Apr.20 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13